专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

11. 发明申请

WO2018052556A1 ENGINEERED POLYPEPTIDES AND USES THEREOF 审中-公开
标题翻译：工程化多肽及其用途
公开(公告)号：WO2018052556A1
公开(公告)日：2018-03-22
申请号：PCT/US2017/045126
申请日：2017-08-02
申请人： VISTERRA, INC.
发明人： VISWANATHAN, Karthik , RAMAKRISHNAN, Boopathy , BOOTH, Brain , NARAYAN, Kristin , WOLLACOTT, Andrew, M.
IPC分类号： C07K16/00 , C07K16/10 , A61K39/00
摘要： Polypeptides, such as antibody molecules and fusion proteins, comprising an Fc region, are disclosed. The polypeptides can be used to treat, prevent, and/or diagnose disorders. In particular, Fc regions comprising either one or multiple mutations selected from the partcicular mutations disclosed in Table 1 are disclosed. Certain of said mutations result in increased affinity for the neonatal Fc receptor (FcRn), and certain of said mutations result in ehnaced half-life of engineered antibodies and also have an impact on effector functions. Particular disclosed mutations are M252Y, S254T, T256E, L309N, T250Q, M428L, N434S, N434A, T307A, E380A, N434A, M252Y, S254T, T256E, or a combination thereof as e.g. T256D/Q311V/A378V, H285N/ T307Q/N315D, H285D/T307Q/A378V, T307Q/Q311V/A378V, T256D/ N286D/T307R/Q311V/A378V, or T256D/T307R/Q311.
摘要翻译：公开了包含Fc区的多肽，例如抗体分子和融合蛋白。多肽可用于治疗，预防和/或诊断疾病。具体而言，公开了包含选自表1中公开的部分突变的一个或多个突变的Fc区。所述突变中的某些导致对新生儿Fc受体（FcRn）的亲和力增加，并且某些所述突变导致工程化抗体的乙酰半胱氨酸半衰期，并且还对效应子功能具有影响。特别公开的突变是M252Y，S254T，T256E，L309N，T250Q，M428L，N434S，N434A，T307A，E380A，N434A，M252Y，S254T，T256E或其组合。 T256D / Q311V / A378V，H285N / T307Q / N315D，H285D / T307Q / A378V，T307Q / Q311V / A378V，T256D / N286D / T307R / Q311V / A378V或T256D / T307R / Q311。

12. 发明申请

WO2017091683A8 ANTIBODY MOLECULES TO APRIL AND USES THEREOF 审中-公开
公开(公告)号：WO2017091683A8
公开(公告)日：2017-06-01
申请号：PCT/US2016/063518
申请日：2016-11-23
申请人： VISTERRA, INC.
发明人： MYETTE, James, R. , SHRIVER, Zachary, Holmes , VISWANATHAN, Karthik , WOLLACOTT, Andrew, M. , ADARI-HALL, Hedy , RAMAKRISHNAN, Boopathy , BABCOCK, Gregory
IPC分类号： C07K16/28 , A61K39/395 , A61K39/00 , A61K2039/505 , A61K2039/54 , A61K39/3955 , A61K45/06 , A61P1/00 , A61P1/16 , A61P13/12 , A61P17/00 , A61P19/02 , A61P29/00 , A61P35/00 , A61P35/02 , A61P37/02 , A61P37/06 , A61P43/00 , A61P7/00 , A61P9/00 , C07K16/241 , C07K16/2875 , C07K2317/14 , C07K2317/24 , C07K2317/33 , C07K2317/34 , C07K2317/52 , C07K2317/56 , C07K2317/76 , C07K2317/92 , C07K2317/94
摘要： Antibody molecules that specifically bind to APRIL are disclosed. The antibody molecules can be used to treat, prevent, and/or diagnose disorders, such as IgA nephropathy.

13. 发明申请

WO2015122995A1 ANTIBODY MOLEULES TO DENGUE VIRUS AND USES THEREOF 审中-公开
标题翻译：抗体病毒侵入病毒及其用途
公开(公告)号：WO2015122995A1
公开(公告)日：2015-08-20
申请号：PCT/US2015/011965
申请日：2015-01-20
申请人： VISTERRA, INC.
发明人： ROBINSON, Luke , SHRIVER, Zachary , MYETTE, James , BABCOCK, Gregory , VISWANATHAN, Karthik
IPC分类号： C07K16/10 , A61K39/00 , A61K39/42
CPC分类号： C07K16/1081 , A61K39/42 , A61K45/06 , A61K2039/505 , A61K2039/545 , C07K2317/14 , C07K2317/24 , C07K2317/33 , C07K2317/54 , C07K2317/55 , C07K2317/565 , C07K2317/567 , C07K2317/622 , C07K2317/76 , C07K2317/90 , C07K2317/92 , C07K2317/94 , G01N33/56983 , G01N2333/185 , Y02A50/386 , Y02A50/53
摘要： Antibody molecules that specifically bind to dengue virus are disclosed. In certain embodiments, the antibody molecule bind to dengue virus serotypes DV-1, DV-2, DV-3, and DV-4. The antibody molecules can be used to treat, prevent, and/or diagnose dengue virus.
摘要翻译：公开了特异性结合登革病毒的抗体分子。在某些实施方案中，抗体分子结合登革病毒血清型DV-1，DV-2，DV-3和DV-4。抗体分子可用于治疗，预防和/或诊断登革热病毒。

14. 发明申请

WO2021146320A8 ANTIBODY MOLECULES TO C5AR1 AND USES THEREOF 审中-公开
公开(公告)号：WO2021146320A8
公开(公告)日：2021-07-22
申请号：PCT/US2021/013284
申请日：2021-01-13
申请人： VISTERRA, INC.
发明人： VISWANATHAN, Karthik , BOOTH, Brian , RAMAKRISHNAN, Boopathy , WOLLACOTT, Andrew , BABCOCK, Gregory , SHRIVER, Zachary
IPC分类号： C07K16/28 , A61P35/00 , A61P37/00 , C07K16/46 , A61K39/395 , A61K2039/505 , C07K16/2896 , C07K2317/31 , C07K2317/33 , C07K2317/34 , C07K2317/35 , C07K2317/76
摘要： Antibody molecules that specifically bind to C5aRl are disclosed. The antibody molecules can be used to treat, prevent, and/or diagnose disorders, such as ANCA-vasculitis.

15. 发明申请

WO2020139834A1 METHODS FOR IDENTIFYING EPITOPES AND PARATOPES 审中-公开
公开(公告)号：WO2020139834A1
公开(公告)日：2020-07-02
申请号：PCT/US2019/068346
申请日：2019-12-23
申请人： VISTERRA, INC.
发明人： WOLLACOTT, Andrew, M. , ROBINSON, Luke , RAMAKRISHNAN, Boopathy , TISSIRE, Hamid , VISWANATHAN, Karthik , SHRIVER, Zachary , BABCOCK, Gregory
IPC分类号： C07K16/28 , G16B20/50 , G16B20/30
摘要： Disclosed are methods of identifying an epitope on a target polypeptide and methods of identifying a paratope on an antibody.

16. 发明申请

WO2018136626A1 ANTIBODY MOLECULE-DRUG CONJUGATES AND USES THEREOF 审中-公开
公开(公告)号：WO2018136626A1
公开(公告)日：2018-07-26
申请号：PCT/US2018/014224
申请日：2018-01-18
申请人： VISTERRA, INC.
发明人： SHRIVER, Zachary , PLANTE, Obadiah, Joseph , LI, Kai , VISWANATHAN, Karthik , DELANEY, James, C. , RAMAKRISHNAN, Boopathy , WOLLACOTT, Andrew, M.
IPC分类号： C07K16/12 , A61K47/68 , A61P31/04
摘要： Antibody molecule-drug conjugates (ADCs) that specifically bind to lipopolysaccharides (LPS) are disclosed. The antibody molecule-drug conjugates can be used to treat, prevent, and/or diagnose bacterial infections and related disorders.

17. 发明申请

WO2018052556A8 ENGINEERED POLYPEPTIDES AND USES THEREOF 审中-公开
公开(公告)号：WO2018052556A8
公开(公告)日：2018-03-22
申请号：PCT/US2017/045126
申请日：2017-08-02
申请人： VISTERRA, INC.
发明人： VISWANATHAN, Karthik , RAMAKRISHNAN, Boopathy , BOOTH, Brian , NARAYAN, Kristin , WOLLACOTT, Andrew, M.
IPC分类号： C07K16/00 , C07K16/10 , A61K39/00
摘要： Polypeptides, such as antibody molecules and fusion proteins, comprising an Fc region, are disclosed. The polypeptides can be used to treat, prevent, and/or diagnose disorders. In particular, Fc regions comprising either one or multiple mutations selected from the partcicular mutations disclosed in Table 1 are disclosed. Certain of said mutations result in increased affinity for the neonatal Fc receptor (FcRn), and certain of said mutations result in ehnaced half-life of engineered antibodies and also have an impact on effector functions. Particular disclosed mutations are M252Y, S254T, T256E, L309N, T250Q, M428L, N434S, N434A, T307A, E380A, N434A, M252Y, S254T, T256E, or a combination thereof as e.g. T256D/Q311V/A378V, H285N/ T307Q/N315D, H285D/T307Q/A378V, T307Q/Q311V/A378V, T256D/ N286D/T307R/Q311V/A378V, or T256D/T307R/Q311.

18. 发明申请

WO2017091683A1 ANTIBODY MOLECULES TO APRIL AND USES THEREOF 审中-公开
标题翻译：抗体分子到四月和使用它
公开(公告)号：WO2017091683A1
公开(公告)日：2017-06-01
申请号：PCT/US2016/063518
申请日：2016-11-23
申请人： VISTERRA, INC.
发明人： MYETTE, James, R. , SHRIVER, Zachary, Holmes , VISWANATHAN, Karthik , WOLLACOTT, Andrew, M. , ADARI-HALL, Hedy , RAMAKRISHNAN, Boopathy , BABCOCK, Gregory
IPC分类号： C07K16/28 , A61K39/395 , A61K39/00
CPC分类号： C07K16/241 , A61K39/3955 , A61K45/06 , A61K2039/505 , A61K2039/54 , C07K16/2875 , C07K2317/14 , C07K2317/24 , C07K2317/33 , C07K2317/34 , C07K2317/52 , C07K2317/56 , C07K2317/76 , C07K2317/92 , C07K2317/94
摘要： Antibody molecules that specifically bind to APRIL are disclosed. The antibody molecules can be used to treat, prevent, and/or diagnose disorders, such as IgA nephropathy.
摘要翻译：公开了特异性结合APRIL的抗体分子。抗体分子可用于治疗，预防和/或诊断疾病，如IgA肾病。

19. 发明公开

EP4277931A1 HUMANIZED COMPLEMENT 5A RECEPTOR 1 ANTIBODIES AND METHODS OF USE THEREOF 审中-实审
公开(公告)号：EP4277931A1
公开(公告)日：2023-11-22
申请号：EP22702569.9
申请日：2022-01-13
申请人： Visterra, Inc.
发明人： VISWANATHAN, Karthik , BOOTH, Brian , RAMAKRISHNAN, Boopathy , WOLLACOTT, Andrew , BABCOCK, Gregory , SHRIVER, Zachary , OLINSKI, Lauren
IPC分类号： C07K16/28 , A61P37/00 , A61K39/395

20. 发明公开

EP4172206A1 ANTIBODY MOLECULES TO APRIL AND USES THEREOF 审中-实审
公开(公告)号：EP4172206A1
公开(公告)日：2023-05-03
申请号：EP21745524.5
申请日：2021-06-24
申请人： Visterra, Inc.
发明人： MYETTE, James, R. , SHRIVER, Zachary , VISWANATHAN, Karthik , WOLLACOTT, Andrew, M. , ADARI-HALL, Hedy , RAMAKRISHNAN, Boopathy , BABCOCK, Gregory , YARBROUGH, Jill , SCHACHTER, Asher , MATHUR, Mohit
IPC分类号： C07K16/28 , A61K39/00 , A61K39/395

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式